

AMENDMENT

A Version With Markings to Show Changes Made is included after Applicant's  
Remarks beginning at page 5.

In the Claims:

Please cancel Claims 11, 25-47, 56, 72-134, 145, and 161 without prejudice as being  
directed to a non-elected group. Please amend Claims 1, 48, 135, and 153, as follows.

1.(Amended) A method of delivering a medicant to an abnormal brain region  
in a mammalian subject, comprising:

administering to a mammalian subject having an abnormal brain region a  
potassium channel activator, said potassium channel activator being an activator of soluble  
guanylyl cyclase, under conditions and in an amount sufficient to increase the permeability to  
the medicant of a capillary or arteriole delivering blood to cells of the abnormal brain region;  
and

administering to the subject simultaneously or substantially simultaneously  
with the potassium channel activator the medicant, so that the medicant is delivered  
selectively to the cells of the abnormal brain region compared to normal brain regions.

48.(Amended) A method of delivering a medicant to a malignant tumor in a  
mammalian subject, comprising:

administering to a mammalian subject having a malignant tumor a potassium  
channel activator, said potassium channel activator being an activator of soluble guanylyl  
cyclase, under conditions and in an amount sufficient to increase the permeability to the  
medicant of a capillary or arteriole delivering blood to cells of the malignant tumor; and

administering to the subject simultaneously or substantially simultaneously  
with the potassium channel activator the medicant, so that the medicant is delivered  
selectively to the malignant cells compared to non-malignant cells.

BEST AVAILABLE COPY